<DOC>
	<DOCNO>NCT01573247</DOCNO>
	<brief_summary>This Phase 1/2 study consist two part . The purpose Part 1 study examine safety tolerability AKN-028 determine recommend dose AKN-028 evaluation Part 2 study patient Acute Myelogenous Leukemia ( AML ) . The purpose Part 2 study determine safety efficacy patient AML .</brief_summary>
	<brief_title>Safety Study AKN-028 Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Provide write informed consent prior Screening ; Male female patient , age ≥ 18 year ; For female childbearing potential , negative urine pregnancy test must obtain Confirmed diagnosis AML ( ≥ 20 % blast bone marrow / peripheral blood ) accord World Health Organization ( WHO ) classification [ 2 ] meeting least one following : 1 . Newly diagnose AML , accord clinical judgment principal investigator , patient candidate induction chemotherapy age , comorbidity , performance status , factor ; 2 . AML first relapse WBC &lt; 60,000/mm3 ineligible intensive induction chemotherapy ; 3 . AML second relapse low peripheral blast count ( &lt; 10,000/mm3 ) WBC &lt; 60,000/mm3 ineligible intensive induction chemotherapy ; 4 . Primary refractory disease , define patient AML achieve CR follow 2 course chemotherapy enrollment Part 1 patient AML refractory follow 1 course chemotherapy enrollment Part 2 ; Note : Severe neutropenia per se ( Grade 4 ) accept likely related AML . However , severe neutropenia may due recently administer chemotherapy ( e.g . cytarabin ) . It may prudent perform new bone marrow examination . In case marrow hypoplastic ( due cytarabin ) screening postpone GCSF administer short period patient reevaluate . In case bone marrow hypoplastic rather infiltrated AML cell patient screen . Performance status 03 Eastern Cooperative Oncology Group ( ECOG ) Performance Status Scale ; Adequate organ function , include follow : Serum creatinine ≤ 2.0 mg/dL ( 176.8 mMol/L ) screening ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2x upper limit normal ( ULN ) screening ; Total bilirubin ≤1.5 x ULN screen . Patients candidate induction chemotherapy AML Total WBC count ≥ 60,000/mm3 ; Evidence active central nervous system ( CNS ) leukemia ; Evidence blastphase chronic myelogenous leukemia ( CML ) ; Histological cytogenetic diagnosis AML M3 subtype ( Acute Promyelocytic Leukemia ) ; Lack recovery nonhematological toxicity systemic therapy underlie hematologic condition ; Previous concurrent malignancy except noninvasive nonmelanoma skin cancer , situ carcinoma cervix , solid tumor treat curatively , without evidence recurrence least 2 year prior study entry ; exclusion refer disease ( AML ) study ; Uncontrolled systemic infection ( viral , bacterial , fungal ) ; Uncontrolled disseminate intravascular coagulation ; Known positive serology human immunodeficiency virus ; Clinically significant cardiac dysfunction ( New York Heart Association Class 3 4 ) time screen , history myocardial infarction heart failure within 3 month precede first dose AKN028 ; Chronic Graft versus Host Disease ( GVHD ) exception mild ( Grade 1 ) skin oral GVHD ; Major surgery within 28 day precede first dose AKN028 ; Concomitant administration antileukemia antineoplastic therapy ( screening period , hydroxyurea allow ≤ 7 day Cycle 1 , well ≤ 7 day cycle ) ; Concomitant treatment immunotherapy , investigational agent within 28 day precede first dose AKN028 , lack recovery toxicity treatment ; Active autoimmune disease require immunosuppressive therapy ; Radiotherapy , lack recovery radiotherapyrelated acute toxicity , within 28 day precede first dose AKN028 ; Previous treatment clinical study AKN028 , FLT3 inhibitor , cKit inhibitor ; Female patient pregnant breastfeeding ; Male , female patient childbearing potential , unwilling use approve , effective mean contraception ( e.g. , oral contraception , barrier contraception , intrauterine device ) accordance investigator 's standard ; Known current drug alcohol abuse ; Active viral Hepatitis B /or C ; Other severe , acute , chronic medical psychiatric condition , laboratory abnormality , opinion investigator , may compromise safety patient study , affect patient 's ability complete study , interfere interpretation study result ; Any condition , judge Investigator inappropriate study participation , include inability communicate cooperate Investigator requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Refractory Acute myeloid leukemia</keyword>
	<keyword>FLT3 inhibitor</keyword>
	<keyword>kinase inhibitor</keyword>
</DOC>